Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study

Código QR

Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study

Huafang Li,1,2 Yan Li,1,2 Yu Feng,3 Jianmin Zhuo,4 Ibrahim Turkoz,5 Maju Mathews,5 Wilson Tan3 1Shanghai Mental Health Centre, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 2Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China; 3Janssen Pharmaceutical Companies of Jo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li H, Li Y, Feng Y, Zhuo J, Turkoz I, Mathews M, Tan W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	early treatment initiation hospital setting long acting injectable Asian Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/6bd490120a0b4905be78c09d2aad6c6a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
por: O'Donnell A, et al.
Publicado: (2021)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
por: Li HF, et al.
Publicado: (2015)

Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
por: El Khoury AC, et al.
Publicado: (2021)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
por: Nash AI, et al.
Publicado: (2019)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
por: Si T, et al.
Publicado: (2019)

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
por: Zhao JP, et al.
Publicado: (2017)

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
por: Mathews M, et al.
Publicado: (2018)

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
por: Savitz AJ, et al.
Publicado: (2019)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
por: Sliwa JK, et al.
Publicado: (2012)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
por: Such P, et al.
Publicado: (2021)

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
por: Savitz AJ, et al.
Publicado: (2017)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Chih-Sung Liang, et al.
Publicado: (2021)

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
por: Emsley R, et al.
Publicado: (2017)

The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies
por: Peters-Strickland T, et al.
Publicado: (2019)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
por: Lopez A, et al.
Publicado: (2019)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews M, et al.
Publicado: (2019)

Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics
por: Li N, et al.
Publicado: (2018)

Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies
por: Madera JJ, et al.
Publicado: (2019)

Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment
por: Madera J, et al.
Publicado: (2019)

Once-monthly paliperidone injection for the treatment of schizophrenia
por: Delia Bishara
Publicado: (2010)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
por: Takada R, et al.
Publicado: (2018)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
por: Emsley R, et al.
Publicado: (2018)

RELATIONSHIP BETWEEN FLORAL MORPHOLOGY, FRUIT SETTING BEHAVIOR AND FINAL YIELD IN SOME EGGPLANT (Solanum melongena) GENOTYPES FROM IRAN
por: Khaleghi,Sedighehsadat, et al.
Publicado: (2021)

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
por: Mathews M, et al.
Publicado: (2020)

Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability
por: Gattaz WF, et al.
Publicado: (2020)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
por: Brasso C, et al.
Publicado: (2017)

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
por: Gopal S, et al.
Publicado: (2020)

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia
por: Lambert M, et al.
Publicado: (2020)

Alcohol dependence is formed on the background of violations of mental adaptation
por: T. V. Agibalova, et al.
Publicado: (2013)

Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation
por: Christoph U. Correll, et al.
Publicado: (2020)

Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia
por: Takahashi N, et al.
Publicado: (2013)

East Asian Forum

The Journal of Asian studies

Asian American policy review
Publicado: (1990)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
por: Zhang F, et al.
Publicado: (2015)

Geo-Setting in the Arctic and Countermeasures of China: A Case Study of the "Polar Silk Road"
por: Ma Teng, et al.
Publicado: (2021)

Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study
por: Si TM, et al.
Publicado: (2015)

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
por: Dhiren Singh, et al.
Publicado: (2009)

Attitudes and Willingness to Accept Long-Acting Injections for Patients With Schizophrenia in Beijing: A Cross-Sectional Investigation Based on Samples From the Communities
por: Junli Zhu, et al.
Publicado: (2021)

South Asian diaspora